GlassScriptPhysician profile
Maurice N Leibman
NPI 1023017001
$9,570.22
in general payments reported to CMS, 2019-2025
36 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,530 · 2020: $830 · 2021: $1,144 · 2022: $1,499 · 2023: $568 · 2024: $3,000.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $1,500 · Consulting Fee: $1,500 · Food and Beverage: $568.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $1,500.00 |
| Consulting Fee | $1,500.00 |
| Food and Beverage | $567.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascend Therapeutics US, LLC | $3,368.89 | 2019-2024 | |
| Acessa Health INC. | $1,088.32 | 2019-2022 | |
| Novo Nordisk INC | $857.89 | 2019-2023 | Wegovy |
| Therapeuticsmd, INC. | $612.02 | 2019-2022 | |
| Abbvie INC. | $597.76 | 2019-2022 | |
| Amgen INC. | $409.00 | 2019-2023 | Evenity, Prolia |
| Mayne Pharma Commercial LLC | $305.54 | 2021-2023 | |
| Pfizer INC. | $269.08 | 2019-2023 | |
| Amag Pharmaceuticals, INC. | $220.15 | 2019-2020 | |
| Myovant Sciences INC. | $192.57 | 2021-2022 | |
| Vertical Pharmaceuticals, LLC | $177.40 | 2019-2020 | |
| Davol INC. | $162.15 | 2022 | |
| Currax Pharmaceuticals LLC | $152.32 | 2019-2023 | Contrave |
| Exeltis, USA INC. | $151.94 | 2019-2023 | Solosec |
| Lupin INC. | $119.15 | 2019-2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avion Pharmaceuticals | $98.06 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $90.52 | 2022-2023 | Seglentis |
| Bayer Healthcare Pharmaceuticals INC. | $82.47 | 2021-2023 | |
| Sumitomo Pharma America, INC. | $82.28 | 2023 | Myfembree |
| Allergan, INC. | $70.43 | 2019-2020 | |
| Astellas Pharma US INC | $61.08 | 2020-2023 | Veozah |
| Evofem Biosciences, INC. | $58.93 | 2021-2022 | |
| Millicent US INC | $45.92 | 2020-2021 | |
| Hologic Sales and Service, LLC | $45.15 | 2019 | |
| Organon LLC | $38.28 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $31.42 | 2022-2023 | Quviviq |
| Merck Sharp & Dohme LLC | $24.66 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.43 | 2019 | |
| Scynexis, INC. | $21.39 | 2022 | |
| Allotrope Medical, INC | $20.00 | 2021 | |
| Shire North American Group INC | $18.40 | 2019 | |
| Eisai INC. | $18.14 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $17.71 | 2021 | |
| Gynesonics, INC. | $15.47 | 2023 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Agile Therapeutics, INC. | $11.31 | 2021 | |
| Nalpropion Pharmaceuticals LLC | $10.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maurice Leibman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.